Results 101 to 109 of about 1,013 (109)

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

Cancer Chemotherapy and Pharmacology, 2021
Jennifer Hibma, Yazdi Pithavala
exaly  

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease

Journal of Thoracic Oncology, 2022
Benjamin Besse, Alice Shaw, Robin Wiltshire   +2 more
exaly  

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Therapeutic Advances in Medical Oncology, 2021
Nikolaj Frost, Petros Christopoulos, Eckart Laack   +2 more
exaly  

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

Advances in Therapy, 2019
Joseph Chen, Yazdi Pithavala
exaly  

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants

Investigational New Drugs, 2019
Joseph Chen, Yazdi Pithavala
exaly  

First macrocyclic 3-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib

European Journal of Medicinal Chemistry, 2017
Zaman Ashraf, Sulman Basit, Muhammad Latif   +2 more
exaly  

Lorlatinib – Induced pulmonary arterial hypertension

Lung Cancer, 2018
Colas Tcherakian, David Montani, Elisabeth Rivaud   +2 more
exaly  

Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report

Journal of Thoracic Oncology
Takayuki Shiroyama, Kotaro Miyake, Atsushi Kumanogoh   +2 more
exaly  

Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma

Pediatric Blood and Cancer
Kim Kramer, Ellen M Basu, Shakeel Modak
exaly